Login to Your Account



Synta's Elesclomol In Pivotal Study In Melanoma Patients

By Trista Morrison


Tuesday, November 13, 2007
A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription